appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Gland Pharma Ltd
GLAND
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Gland Pharma is engaged in manufacturing small volume parenterals (SVPs) and contract development services.
Investor PresentationView older
View Older PresentationsPeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Zydus Lifesciences Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Increased Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has increased by 1.67%
Recent NewsAll news
Stock alert: Gland Pharma, Gujarat Fluorochem, Ujjivan SFB, Prestige Estates, IREDA
1 week ago•Business Standard
Stock alert: Indus Towers, Gland Pharma, Advanced Enzyme, DMart, Sapphire Foods
2 weeks ago•Business Standard
Gland Pharma promoter Fosun divests 6% stake for Rs 1,754 cr via bulk deal
2 weeks ago•Business Standard
Recent EventsAll events
Allotment of Securities
Gland Pharma Limited has informed the Exchange regarding allotment of 41200 securities pursuant to ESOP/ESPS at its meeting held on Jun 07, 2024 | Download
Gland Pharma Limited has informed the Exchange regarding allotment of 41200 securities pursuant to ESOP/ESPS at its meeting held on Jun 07, 2024 | Download
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant